ArticleAdvanced biomedical research2025
Correlation of Sclerostin Serum Levels with the Pathogenesis of Coronary Artery Disease.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sclerostin is primarily known for its role in inhibiting bone formation; however, emerging evidence suggests that it may also play a role in vascular health. Coronary artery disease (CAD) is a heart condition characterized by the narrowing or blockage of the coronary arteries. The relationship between sclerostin and CAD is complex and not yet fully understood. The presented study was to investigate a novel perspective on sclerostin by evaluating its levels as a potential marker for diagnosing stable CAD and examining its relationship with cardiac biochemical variables. Materials and Methods: A total of 160 individuals participated in this study, divided into two groups: 80 patients with stable coronary heart disease (CHD) and 80 individuals in the control group. Results: The result showed a highly significant decrease in sclerostin levels in the serum of the patient group (71.256 pg/mL) compared to the control group (98.426 pg/mL). In addition, there was a significant reduction in the level of sclerostin in all patient subgroups compared to the control subgroups, according to age. Additionally, there were significant differences ( Conclusion: Sclerostin may play a crucial role in the development of CAD and could serve as a marker for diagnosing and monitoring its progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.